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The C terminus of the catalytic g-subunit of phospho-
rylase kinase comprises a regulatory domain that con-
tains regions important for subunit interactions and
autoinhibitory functions. Monospecific antibodies
raised against four synthetic peptides from this region,
PhK1 (362–386), PhK5 (342–366), PhK9 (322–346), and
PhK13 (302–326), were found to have significant effects
on the catalytic activities of phosphorylase kinase hol-
oenzyme and the gzd complex. Antibodies raised against
the very C terminus of the g-subunit, anti-PhK1 and
anti-PhK5, markedly activated both holoenzyme and the
gzd complex, in the presence and absence of Ca21. In the
presence of Ca21 at pH 8.2, anti-PhK1 activated the hol-
oenzyme more than 11-fold and activated the gzd com-
plex 2.5-fold. Activation of the holoenzyme and the gzd
complex by anti-PhK5 was 50–70% of that observed with
anti-PhK1. Prior phosphorylation of the holoenzyme by
the cAMP-dependent protein kinase blocked activation
by both anti-PhK1 and anti-PhK5. Antibodies raised
against the peptides from the N terminus of the regula-
tory domain, anti-PhK9 and anti-PhK13, were inhibi-
tory, with their greatest effects on the gzd complex.
These data demonstrate that the binding of antibodies
to specific regions within the regulatory domain of the
g-subunit can augment or inhibit structural changes
and subunit interactions important in regulating phos-
phorylase kinase activity.
Phosphorylase kinase (ATP:phosphorylase phosphotrans-
ferase, EC 2.7.1.38) catalyzes the conversion of phosphorylase b
to a and plays a key role in regulating glycogen breakdown in
response to adrenergic and neuronal stimuli. The skeletal mus-
cle isozyme is a multimeric enzyme with the subunit composi-
tion (abgd)4 and a molecular weight of 1.3 3 10
6 (reviewed in
Ref. 1). The a-, b-, and d-subunits are regulatory subunits,
whereas the g-subunit is the catalytic subunit (2). Interactions
of the regulatory subunits with the g-subunit serve to modulate
the activity of the enzyme in response to the second messen-
gers, cAMP and Ca21. Phosphorylation of the a- and b-subunits
by the cAMP-dependent protein kinase and by autophospho-
rylation activates the enzyme at pH 6.8. The unphosphorylated
a- and b-subunits are thought to inhibit the catalytic site from
exhibiting maximum catalytic potential, since inhibition can be
relieved by increasing pH to 8.2, by phosphorylation, by prote-
olysis, or by dissociation of these subunits from the holoenzyme
complex. Ca21 dependence is conferred upon the enzyme by the
d-subunit, which is identical to calmodulin (3).
Residues 19–276 of the g-subunit represent the catalytic
domain of the enzyme based on sequence homology with other
protein kinases (2). Two crystal structures of a constitutively
active catalytic core of the g-subunit (residues 1–298) have
recently been solved to a resolution of 3.0 Å or better (4).
Overall, these two g-subunit structures are very similar to the
catalytic cores of other protein kinases. The C-terminal 110
amino acids of the g-subunit (277–386) are thought to contain
pseudosubstrate/autoinhibitory domains and subunit interac-
tion domains based on this region’s lack of sequence similarity
to other protein kinases (2) and studies involving limited pro-
teolysis (5) and site-directed mutagenesis (6–8). By using a
library of overlapping synthetic g-subunit peptides, the regions
corresponding to g302–326 and g342–366 have been identified
as being regulatory subdomains that act in concert to mediate
interactions between the g-subunit and the catalytic domain of
the g-subunit (6, 9, 10). Peptides corresponding to these two
regions (termed PhK13 and PhK5, respectively) bind calmod-
ulin with high affinity (9) and competitively inhibit phospho-
rylase kinase catalytic activity (6, 10). Site-directed mutagen-
esis experiments (6) and small-angle scattering studies (11)
have provided limited structural information regarding the
interactions of PhK5 and PhK13 with the g-subunit catalytic
domain (6) and the d-subunit (11). However, detailed informa-
tion regarding the structure of the g-subunit regulatory domain
is not presently available. It has also been proposed that the
regulatory domain of the g-subunit might interact directly with
the a- and b-subunits (2), but the sites of interaction on the
g-subunit for the a- and b-subunits have yet to be firmly
established.
The present investigation was undertaken to better define
the potential regulatory functions of specific regions within the
regulatory domain of the g-subunit of phosphorylase kinase.
Antibodies were raised against each of four peptides, PhK1
(g362–386), PhK5 (g342–366), PhK9 (g322–346), and PhK13
(g302–326), that together span the C-terminal 85 amino acids
of the g-subunit (Fig. 1). These monospecific antibodies were
then affinity-purified and assayed for their ability to activate or
inhibit the catalytic activity of several different forms of phos-
phorylase kinase. The approach of using antipeptide antibodies
as probes to assess the functional properties of putative regu-
latory domains within protein kinases has previously been
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used to characterize the calmodulin-binding domain of rabbit
skeletal muscle myosin light chain kinase (12), the pseudosub-
strate domain of protein kinase C (13), and potential regulatory
domains in casein kinase II (14), the insulin-like growth fac-
tor-I receptor kinase (15, 16), and rhodopsin kinase (17). The
results of the studies presented here indicate that binding of
monospecific antibodies to the regulatory domain of the g-sub-
unit can have profound effects on catalytic activity and provide
important insights into structural features involved in regula-
tory interactions in the phosphorylase kinase holoenzyme
complex.
EXPERIMENTAL PROCEDURES
Preparation of Phosphorylase b, Phosphorylase Kinase Holoenzyme,
and dzg Complex—Phosphorylase kinase holoenzyme was prepared by
the procedure of Cohen (18), and phosphorylase b was prepared using
the procedure of Fischer and Krebs (19). Protein concentrations were
determined spectrophotometrically using values of E280 nm
1% of 12.4 (18)
and 13.2 (20) for phosphorylase kinase and phosphorylase b, respec-
tively. The g-subunit of phosphorylase kinase was purified using re-
versed-phase HPLC1 as described by Crabb and Heilmeyer (21), except
that a Vydac C-4 analytical column (5 mm, 0.46 3 25 cm) was used
instead of a Vydac C-18 column. The subunit elution pattern obtained
using the C-4 column was similar to that reported for the C-18 column.
The active dzg complex was prepared from HPLC-purified g-subunit
using the reactivation procedure described by Kee and Graves (22). The
reactivation buffer contained 50 mM Tris, 50 mM b-glycerophosphate,
pH 8.0, 2 mM dithiothreitol, 0.1 mM CaCl2, 3 mM calmodulin, 1 mg/ml
bovine serum albumin, and HPLC-purified g-subunit (diluted 10-fold
into the reactivation buffer). Reactivation was carried out at 0 °C for
18 h.
Peptide Synthesis—Synthesis of peptides was done by standard solid-
phase techniques using t-butoxycarbonyl chemistry as described previ-
ously (9). Peptide purification was performed using reversed-phase
HPLC, and each sequence was confirmed by amino acid analysis and
protein sequence analysis.
Antibody Production and Purification—Monospecific polyclonal an-
tibodies were raised in rabbits against the synthetic peptides PhK1
(g362–386), PhK5 (g342–366), PhK9 (g322–346), and PhK13 (g302–
326), which span the C-terminal 85 residues of the g-subunit (see Fig.
1). In the case of PhK1, PhK5, and PhK9, the peptides were coupled to
keyhole limpet hemocyanin using glutaraldehyde, and then each pep-
tide was used to immunize two rabbits using the Ribi Adjuvant System
(Hamilton, MT). Booster injections were given on days 14 and 28 and
every month thereafter. Rabbits were bled each week (3 times a month)
between immunizations. In the case of PhK13, the peptide was coupled
to Imject maleimide-activated keyhole limpet hemocyanin (Pierce) and
used to immunize two rabbits. These rabbits were immunized and bled
by Bethyl Laboratories (Montgomery, TX) according to their recom-
mended schedule. Initial screening using an enzyme-linked immu-
nosorbent assay (ELISA) was performed to select the rabbits giving the
best responses and the bleeds with the highest titer against phospho-
rylase kinase holoenzyme. These antisera were used for the subsequent
workup described below.
Each antiserum was subjected to the following prepurification pro-
cedure to remove contaminating lipids and lipoproteins. To each milli-
liter of antiserum, 0.05 ml 5% (w:v) sodium dextran sulfate (Pharmacia
Biotech Inc.) was added, stirred, then allowed to sit on ice for 1 h. To
this solution was added 0.09 ml of 11.1% (w/v) CaCl2/ml of antiserum.
The solution was allowed to settle on ice for 1–2 h, and the precipitate
was removed by centrifugation at 5000 3 g for 20 min. To further purify
the antipeptide antibodies, the supernatant was subjected to ammo-
nium sulfate fractionation by slowly adding, while stirring, 0.667 ml of
saturated ammonium sulfate (pH 7.3)/ml of antibody solution. The
solution was allowed to stir for 1 h on ice and then was centrifuged at
5000 3 g for 25 min. The precipitated pellet was resuspended in a
minimal volume of Milli-Q water and then dialyzed overnight against
Milli-Q water at 4 °C. The dialysate was then subjected to affinity
purification using phosphorylase kinase immobilized to Sepharose 4B.
Phosphorylase kinase holoenzyme was immobilized on CNBr-acti-
vated Sepharose 4B at a density of 5 mg of protein/ml of gel to produce
affinity columns for the isolation of each of the antipeptide antibodies.
Dry CNBr-activated Sepharose (1.14 g; Sigma) was suspended in 1 mM
HCl to dissolve stabilizers and hydrate the gel. After about 1 min, the
suspension was filtered, and to the moist gel was added 20 mg of
phosphorylase kinase dissolved in 0.1 M borate, 0.5 M NaCl, pH 8.3. The
gel and phosphorylase kinase were gently shaken for 24 h at 4 °C, after
which the suspension was mixed with 1 M ethanolamine and shaken at
room temperature for another 2 h to block unreacted sites on the gel.
The gel was washed with 0.1 M borate, 0.5 M NaCl, pH 8.3, followed by
0.1 M acetic acid, 0.5 M NaCl, pH 4.0, and was then aliquoted into four
1-ml columns. The columns were stored in 50 mM MOPS, 2 mM EDTA,
pH 7.0, at 4 °C. Before use, the columns used for purification of anti-
PhK1 and anti-PhK5 were equilibrated with buffer containing 50 mM
MOPS, pH 7.0, 1 mM dithiothreitol, and 1 mM leupeptin. The columns
used for anti-PhK9 and anti-PhK13 were preequilibrated with the
above buffer containing 200 mM CaCl2. Antipeptide antibodies were
applied to the columns in the presence (anti-PhK9 and anti-PhK13) or
absence (anti-PhK1 and anti-PhK5) of 200 mM Ca21. The columns were
then washed with equilibration buffer until the A280 of the column
effluent was less than 0.05. The anti-PhK1 and anti-PhK5 antibodies
were eluted with 500 mM MgCl2, and the anti-PhK9 and anti-PhK13
antibodies were eluted with 50 mM MOPS, pH 7.0, 1 mM dithiothreitol,
1 mM leupeptin, and 2 mM EDTA. Eluates were desalted using Bio-Gel
P6 DG (Bio-Rad) desalting columns and stored in phosphate-buffered
saline at 4 °C. Antibody concentrations were determined spectrophoto-
metrically using a E280 nm
1% value of 15 for IgG (23).
Fab fragments were prepared from affinity-purified anti-PhK1 anti-
body according to the procedure of Gibson et al. (24) as briefly described
here. A sample of affinity-purified antibody (0.5 mg) was dialyzed
overnight at pH 7.5 against 50 mM Tris-HCl, 0.15 M NaCl, and 2 mM
EDTA. After dialysis, dithioerythritol was added to a final concentra-
tion of 1 mM. A suspension of mercuripapain (Sigma) was prepared in
the above buffer in the presence of 10 mM dithioerythritol. The solutions
of protease and antibody were mixed in a ratio of 1:33 (w:w) and
incubated at 37 °C for 30 min. The reaction was stopped by the addition
of dehydroascorbic acid to a final concentration of 1 mM, and the solu-
tion was allowed to sit for 15 min. The solution was filtered (0.22-mm
filter, Pharmacia), and the Fab fragments were separated by fast pro-
tein liquid chromatography using a Superdex 200 prep grade (HiLoad
16/60) column.
A sandwich ELISA method was used to determine the ability of
anti-PhK1 Fab fragments to bind phosphorylase kinase and the gzd
complex. The procedure used the reagents and protocol provided in the
ELISAmate kit (Kirkegaard and Perry Laboratories). Polystyrene mi-
crotiter plates (96-well flat-bottom, Corning) were first coated with the
indicated concentrations of anti-PhK1 or anti-PhK1 Fab fragment for
1 h at room temperature. Either phosphorylase kinase holoenzyme (0.9
mg/ml) or gzd complex in 1% (w/w) bovine serum albumin was then
added and allowed to bind for 1 h before the plate was emptied and
rinsed with 1% bovine serum albumin. Antibody raised against a syn-
thetic multiple antigen peptide corresponding to the N terminus of the
g-subunit, GKSHSGPLAADRT, was then added (0.7 mg/ml in 1% bovine
serum albumin) and allowed to bind for 1 h. The plate was then emptied
and washed three times with 0.02% Tween 20 (v/v). Peroxidase-labeled
goat anti-rabbit IgG (0.3 mg/ml in 1% bovine serum albumin) was added
and incubated for 1 h. The plate was then washed three times (0.02%
Tween 20) before adding the color development reagents, 3,39,5,59-
tetramethylbenzidine and hydrogen peroxide. The plate was read in
kinetic mode on a UVmax microplate reader (Molecular Devices) at 650
nm using SOFTmax (version 2.01) for data acquisition and analysis.
Phosphorylase Kinase and gzd Complex Activity Assay—A radioactive
1 The abbreviations used are: HPLC, high performance liquid chro-
matography; MOPS, 4-morpholinepropanesulfonic acid; ELISA, en-
zyme-linked immunosorbent assay.
FIG. 1. Nomenclature of synthetic g-subunit (PhK) peptides
used for raising monospecific antisera. Each peptide also carries a
C-terminal Gly-amide residue, which is not shown.
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protein kinase assay was used to monitor antipeptide antibody inter-
actions with phosphorylase kinase holoenzyme and the gzd complex.
Enzymatic activities of the holoenzyme and the gzd complex were de-
termined by measuring the rate of 32P incorporation from [g-32P]ATP
into phosphorylase b or a synthetic peptide substrate (SDQEKRKQIS-
VRGLG). The reaction mixture (50 ml) contained 50 mM HEPES, 42 mM
Tris, 1 mM dithiothreitol, pH 8.2 or 6.8 (as indicated), 10 mM magne-
sium acetate, 200 mM CaCl2, 25 mM phosphorylase b or 250 mM peptide
substrate (as indicated), 100 ng of phosphorylase kinase, and 1 mM
[g-32P]ATP (300 cpm/pmol; DuPont NEN). The reaction mixtures were
preincubated for 5 min at 30 °C before the reactions were started by the
addition of ATP. Aliquots of 10 or 20 ml of each reaction were removed
after 5 and 15 min and spotted on Whatman 3MM or P81 filter paper
squares. Whatman 3MM paper squares were used for the protein sub-
strate, and P81 filter paper squares were used for the synthetic peptide
substrate. The paper squares were immediately placed in 10% trichlo-
roacetic acid, 4% sodium pyrophosphate (3MM paper) or 75 mM H3PO4
(P81 paper). The papers were washed at least three times, rinsed in
95% ethanol, dried, and counted in a scintillation counter following the
addition of Opti-fluor (Packard Instrument Co.) scintillation mixture.
Assays containing antibodies or Fab fragments were performed as
described above except that the enzyme was preincubated on ice (in a
volume of 10 ml) with the indicated concentrations of antibody or Fab
fragment for the indicated times before addition to the protein kinase
reaction mixture.
cAMP-dependent Protein Kinase Activation—Phosphorylase kinase
(2 mg/ml) was activated by incubation with 0.02 milliunits of cAMP-de-
pendent protein kinase catalytic subunit (Promega; units of activity are
as defined by Promega) and 1 mM ATP for 30 min in a volume of 100 ml
in the presence of the pH 6.8 kinase assay buffer described above. The
protein kinase-activated phosphorylase kinase was then preincubated
with antibody and assayed as described above.
Statistical Analysis—Error bars associated with each data set rep-
resent standard errors of the mean calculated from duplicate or tripli-
cate assay tubes, each of which was sampled at two time points. In some
cases, the data represent means and standard errors from more than
one experiment. Nonlinear least squares curve-fitting was performed
using MacCurveFit (version 1.03) to estimate Km and Vmax values and
to determine partial inhibition constants.
RESULTS
Activation of Phosphorylase Kinase by Antipeptide Antibod-
ies—The ability of each affinity-purified antipeptide antibody
to alter the enzymatic activity of phosphorylase kinase holoen-
zyme (Fig. 2) and gzd complex (Fig. 3) at pH 8.2 was examined.
Two of the antibodies, anti-PhK1 and anti-PhK5, induced ac-
tivation of both phosphorylase kinase and the gzd complex in
the presence and absence of Ca21. In the presence of Ca21,
anti-PhK1 antibody increased holoenzyme activity by approx-
imately 1150% and the gzd complex activity by 250%. The
degree of holoenzyme activation induced by anti-PhK5 anti-
body was approximately 70% of that seen with anti-PhK1 an-
tibody and somewhat less (50%) for the gzd complex. The extent
of holoenzyme and gzd complex activation induced by anti-
PhK1 in the presence of 3 mM EGTA was greater than that seen
in the presence of Ca21 with no antibody present. The extent of
stimulation of holoenzyme and gzd complex activity by anti-
PhK5 in the presence of 3 mM EGTA was nearly equal to the
Ca21-stimulated activity in the absence of antibody. The con-
centration of anti-PhK1 required for activation was comparable
for the holoenzyme and the gzd complex, in the presence or
absence of Ca21, with maximal activation occurring at an an-
tibody concentration of 0.3 mg/ml (data not shown).
To determine whether the activation of phosphorylase ki-
nase by anti-PhK1 required antibody with intact Fc regions,
Fab fragments of anti-PhK1 were tested for their ability to
activate the holoenzyme and the gzd complex. Other antipep-
tide antibodies were not investigated due to difficulties in pu-
rifying these other antibodies in sufficient quantities to conduct
such studies. The anti-PhK1 Fab fragments were unable to
activate either the holoenzyme or the gzd complex (Fig. 4). A
sandwich ELISA was used to determine whether the inability
of the Fab fragments to activate was due to the loss of binding
capability. It was found that the anti-PhK1 Fab fragments
were still able to bind holoenzyme and the gzd complex as
tightly as the intact antibody (Fig. 5).
The time dependence of antibody activation was assessed by
measuring holoenzyme and gzd complex activity after overnight
and 1-h incubations. Antibody-induced activation by anti-PhK5
occurred in a time-dependent manner with holoenzyme but not
with the gzd complex (data not shown). Anti-PhK1 exhibited no
difference between the overnight and 1-h incubations in the
extent of activation of either holoenzyme or the gzd complex.
To examine the possible mechanisms for antibody-induced
activation, kinetic analyses were performed with anti-PhK1
and anti-PhK5 antibody using both the holoenzyme and the gzd
complex in the presence and absence of Ca21 at pH 6.8. The Km
and Vmax values determined from these analyses are shown in
Table I. In the presence of Ca21, the effects of both anti-PhK1
and anti-PhK5 on holoenzyme activity were primarily attrib-
utable to changes in Vmax, with only modest or minimal effects
on Km values for ATP or phosphorylase b. Because of the
intrinsic difficulty in accurately determining Km values, it is
difficult to know whether the 2-fold decrease in Km value for
ATP seen with anti-PhK1 and the comparable effect of anti-
PhK5 on the Km value for phosphorylase b are due to normal
assay variability or whether these lower Km values reflect real
but modest effects of these antibodies on enzyme-substrate
interactions. The effects of anti-PhK1 and anti-PhK5 on hol-
FIG. 2. Effect of overnight incubation with affinity-purified
antipeptide antibodies on phosphorylase kinase holoenzyme
activity. Phosphorylase kinase holoenzyme was assayed at pH 8.2 in
the presence of antipeptide antibodies as described under “Experimen-
tal Procedures.” The horizontal dashed line at 100% represents the
Ca21-stimulated activity in the absence of antibody. Error bars repre-
sent the standard error of the mean. *, not determined.
FIG. 3. Effect of affinity-purified antipeptide antibodies on gzd
complex activity in the presence of Ca21 or EGTA. The gzd com-
plex was incubated in the presence of antipeptide antibodies and as-
sayed at pH 8.2 as described under “Experimental Procedures.” The
horizontal dashed line represents the Ca21-stimulated activity of the
gzd complex in the absence of antibody. Error bars represent the stand-
ard error of the mean.
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oenzyme Vmax values were much more robust, with anti-PhK1
increasing Vmax values 10–13-fold and anti-PhK5 increasing
Vmax values 7–9-fold.
Slightly different kinetic patterns were observed for holoen-
zyme activation when the Ca21 concentration was lowered
using EGTA, although the effect of antibody was still predom-
inantly a Vmax effect. Assays of the holoenzyme with varying
concentrations of phosphorylase b in the presence of 3 mM
EGTA resulted in a 9.3-fold increase in Vmax with anti-PhK1
antibody but an increase of only 3.2-fold with anti-PhK5 anti-
body (Table I). There were also 4-fold and 2.4-fold decreases in
the Km value for phosphorylase b with anti-PhK1 antibody and
anti-PhK5 antibody, respectively. Kinetic analyses using ATP
as the varied substrate indicated there were no significant
differences in Km values for ATP, but there were 22.5- and
7-fold increases in Vmax values with anti-PhK1 and anti-PhK5
antibodies, respectively. These observations indicate that in
the absence of Ca21, anti-PhK1 and anti-PhK5 both activate
the holoenzyme through a mixed type mechanism, which is
mostly due to an effect on Vmax, but with some rate-enhancing
effects on the Km for phosphorylase b and no effect on the Km
for ATP.
The kinetic patterns observed for activation of the gzd com-
plex by anti-PhK1 and anti-PhK5 were similar overall to those
seen with the holoenzyme, with activation being predomi-
nantly a Vmax effect (Table I). Differences between holoenzyme
activation and gzd complex activation were primarily seen in
the extent of activation and the somewhat more complex pat-
tern of gzd complex activation observed with anti-PhK1 in the
presence of Ca21. A 4-fold decrease in the Km value for phos-
phorylase b and a 2-fold increase in the Vmax was seen when
the gzd complex was assayed with anti-PhK1 antibody in the
presence of Ca21, indicating a mixed type activation, which
differs from the pure Vmax effect seen with the holoenzyme. A
1.7-fold increase in Vmax was seen with the anti-PhK5 anti-
body, with no significant change in Km for phosphorylase b.
With regard to ATP, there was no significant change in Km
value observed with anti-PhK1 and a 2-fold increase with anti-
PhK5, whereas the Vmax value increased 3- and 1.7-fold with
anti-PhK1 and anti-PhK5, respectively. The effects of anti-
PhK1 and anti-PhK5 on the Km and Vmax values of the gzd
complex in the presence of EGTA were qualitatively the same
as those seen in the presence of Ca21, with Vmax effects always
being observed and Km effects being seen to a variable degree.
Phosphorylase kinase is activated by cAMP-dependent pro-
tein kinase-catalyzed phosphorylation of its a- and b-subunits.
In order to determine if activation by phosphorylation affects
the activation induced by the anti-PhK1 and anti-PhK5, anti-
body activation assays were performed using holoenzyme acti-
vated by cAMP-dependent protein kinase (Fig. 6). Activation by
cAMP-dependent protein kinase resulted in a 4-fold stimula-
tion of activity, which is comparable with the 3.8-fold stimula-
tion in Vmax induced by raising the pH from 6.8 to 8.2 with this
preparation of phosphorylase kinase (data not shown). The
activation induced either by anti-PhK1 (13-fold) or by anti-
PhK5 (8-fold) was significantly greater than the activation seen
with cAMP-dependent protein kinase. Interestingly, cAMP-de-
pendent protein kinase activation of phosphorylase kinase
completely blocked subsequent activation of the holoenzyme by
either antibody (Fig. 6).
Inhibition of Phosphorylase Kinase Activity by Antipeptide
Antibodies—In contrast to the activation seen with anti-PhK1
and anti-PhK5, both anti-PhK9 and anti-PhK13 caused inhibi-
tion of holoenzyme and gzd complex activity (Figs. 2 and 3;
Table I). Inhibition of holoenzyme activity by anti-PhK9 was
modest (20%) and maximal after 1 h of incubation (data not
shown). Holoenzyme inhibition by anti-PhK13 was more pro-
FIG. 4. Activity of phosphorylase kinase holoenzyme and the
gzd complex in the presence of Fab fragments of anti-PhK1.
Phosphorylase kinase holoenzyme (A) or the gzd complex (B) were pre-
incubated with affinity-purified anti-PhK1 antibody or anti-PhK1 Fab
fragments in the presence of Ca21 (1 mM) or EGTA (3 mM) and then
assayed at pH 8.2 as described under “Experimental Procedures.” Error
bars represent the standard error of the mean from three independent
assays (each performed in duplicate). The horizontal dashed line rep-
resents Ca21-stimulated enzyme activity in the absence of antibody.
FIG. 5. Binding of anti-PhK1 antibody (filled symbols) and an-
ti-PhK1 Fab fragments (open symbols) to phosphorylase kinase
holoenzyme and the gzd complex as determined by sandwich
ELISA. Data obtained using anti-PhK1 antibody are represented by
filled symbols, and anti-PhK1 Fab data are represented by open sym-
bols. Data obtained using holoenzyme are depicted by square symbols,
while those obtained using the gzd complex are represented by circles.
Details of the sandwich ELISA are described under “Experimental
Procedures.” Each point represents the mean of three independent
assays (each with quadruplicate wells) 6 S.D.
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nounced but slower, with less than 20% inhibition occurring
after 1 h and ;50% inhibition being reached after 24 h (data
not shown). When either anti-PhK9 or anti-PhK13 was incu-
bated with the gzd complex, a relatively slow onset of inhibition
was observed (data not shown). After a 1-h incubation of the gzd
complex with anti-PhK9 antibody there was only slight inhibi-
tion (;10%), whereas anti-PhK13 elicited nearly complete in-
hibition (90%) after 1-h. Both anti-PhK9 and anti-PhK13
caused nearly complete inhibition (98%) of gzd complex activity
with overnight incubation.
Kinetic studies of anti-PhK13 inhibition of holoenzyme ac-
tivity indicate a noncompetitive mode of inhibition with a 1.7-
fold decrease in Vmax value and little or no effect on the Km
value for either ATP or phosphorylase b (Table I). Inhibition of
holoenzyme by anti-PhK13 was concentration-dependent and
saturable (Fig. 7). With saturating concentrations of anti-
PhK13, only a partial (;50%) inhibition of the holoenzyme was
obtained (Fig. 7), whereas essentially complete inhibition (99%)
was seen with the gzd complex (Fig. 3). Thus, anti-PhK13 acts
as a partial inhibitor of the holoenzyme (25) but a full inhibitor
of the gzd complex. A kinetic scheme illustrating partial non-
competitive inhibition of holoenzyme activity as seen with anti-
PhK13 is depicted in Fig. 8. For the sake of simplicity, only one
substrate is shown. In this scheme, anti-PhK13 antibody is
represented as I, which is able to bind free enzyme (E) as well
as the enzyme-substrate complex (ES). Inhibitor binding to the
enzyme has no effect on substrate binding (Ks), and conversely,
substrate binding has no effect on inhibitor binding (Ki). The
catalytic efficiency of the enzyme-substrate-inhibitor complex
(ESI), is reduced relative to the enzyme-substrate complex, and
this is reflected in the term a, the partial inhibition coefficient.
TABLE I
Summary of kinetic data for antibody activation and inhibition of holoenzyme and gzd complex activity
Vmax and Km values for ATP and phosphorylase b at pH 6.8 were determined by nonlinear curve fitting of initial rate data using MacCurveFit
(version 1.03). The errors associated with each value are 95% confidence intervals. Values in parentheses were determined from linear regression
of double reciprocal plots. Initial rates were determined as described under “Experimental Procedures” using phosphorylase b concentrations
varying from 10 to 100 mM at a fixed concentration of ATP (1 mM) and ATP concentrations ranging from 0.25 to 1 mM at a fixed concentration of
phosphorylase b (25 mM). All experiments were done in duplicate at two time points and repeated at least three times. Control reactions were
handled in the same manner as those with antibody, except that no antibody was added.
Phosphorylase b ATP
Km Vmax Km Vmax
mM mmol/min/mg mM mmol/min/mg
Phosphorylase kinase holoenzyme in the presence of Ca21 (1 mM)
Control 64.0 6 3.16 (53.2) 2.23 6 0.05 (2.01) 0.25 6 0.03 (0.33) 1.37 6 0.06 (1.55)
Anti-PhK1 55.8 6 8.11 (55.9) 28.8 6 1.96 (28.9) 0.13 6 0.01 (0.21) 13.9 6 0.04 (15.7)
Anti-PhK5 32.7 6 7.51 (38.6) 14.8 6 1.26 (15.9) 0.26 6 0.01 (0.25) 12.7 6 0.24 (12.6)
Anti-PhK13 65.9 6 13.8 (53.3) 1.34 6 0.14 (1.20) 0.31 6 0.05 (0.48) 0.79 6 0.05 (0.96)
Phosphorylase kinase holoenzyme in the absence of Ca21 (3 mM EGTA)
Control 69.0 6 11.2 (49.7) 0.49 6 0.04 (0.61) 0.19 6 0.06 (0.17) 0.39 6 0.04 (0.38)
Anti-PhK1 17.5 6 10.1 (23.1) 4.56 6 0.77 (5.04) 0.45 6 0.05 (0.73) 8.79 6 0.46 (11.4)
Anti-PhK5 28.9 6 10.2 (24.2) 1.57 6 0.20 (1.50) 0.42 6 0.06 (0.50) 2.70 6 0.15 (2.94)
gzd complex in the presence of Ca21 (1 mM)
Control 47.9 6 9.57 (31.5) 1.76 6 0.15 (1.46) 0.13 6 0.02 (0.15) 1.02 6 0.03 (1.06)
Anti-PhK1 12.5 6 3.00 (17.0) 3.81 6 0.22 (4.13) 0.10 6 0.01 (0.09) 3.00 6 0.06 (2.94)
Anti-PhK5 31.2 6 11.2 (38.5) 2.94 6 0.38 (3.17) 0.27 6 0.05 (0.27) 1.71 6 0.11 (1.72)
gzd complex in the absence of Ca21 (3 mM EGTA)
Control 59.5 6 9.37 (72.4) 0.41 6 0.03 (0.45) 0.21 6 0.04 (0.27) 0.37 6 0.02 (0.41)
Anti-PhK1 16.7 6 5.25 (26.2) 1.43 6 0.12 (1.65) 0.14 6 0.01 (0.15) 1.49 6 0.03 (1.52)
Anti-PhK5 85.2 6 26.9 (96.9) 2.06 6 0.36 (2.16) 0.11 6 0.02 (0.12) 0.75 6 0.03 (0.78)
FIG. 6. Activity of cAMP-dependent protein kinase-activated
phosphorylase kinase holoenzyme in the presence of anti-PhK1
and anti-PhK5 antibody. Phosphorylase kinase was activated by
cAMP-dependent protein kinase and then incubated with or without
anti-PhK1 or anti-PhK5 antibody, as indicated, before assaying for
activity at pH 6.8. Conditions used for activation and for the phospho-
rylase kinase assay are described under “Experimental Procedures.”
Error bars represent the standard error of the mean of three independ-
ent assays (each performed in duplicate).
FIG. 7. Concentration dependence of phosphorylase kinase
holoenzyme activity by affinity-purified anti-PhK13 antibody.
Phosphorylase kinase holoenzyme was incubated overnight with the
indicated concentrations of anti-PhK13 antibody and then assayed at
pH 8.2 as described under “Experimental Procedures.” The data were fit
to the equation for partial noncompetitive inhibition (Fig. 8). The curve
shown was calculated using the equation shown in Fig. 8 and the best
fit values determined by MacCurveFit (version 1.03). Each point rep-
resents the mean of three independent assays (each performed in du-
plicate) 6 the standard error of the mean.
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In the case of pure noncompetitive inhibition, a 5 0. Estimates
of a (0.589 6 0.028) and Ki (0.035 6 0.014 mg/ml) were deter-
mined for anti-PhK13 from nonlinear least squares curve fit-
ting of the data in Fig. 7 using the equation shown in Fig. 8.
The curve calculated using these best fit values is plotted in
Fig. 7.
Because it has recently been shown that the pseudosub-
strate/autoinhibitory domain of the g-subunit is rather exten-
sive and involves the regions corresponding to both PhK5 and
PhK13 (6, 10), it was important to determine whether using a
minimal length phosphate-acceptor substrate might have any
effect on antibody-induced activation or inhibition. Fig. 9 shows
the results of assays performed in the presence of anti-PhK1,
anti-PhK5, and anti-PhK13 using a tetradecapeptide peptide
substrate corresponding to the phosphorylation site of phos-
phorylase b in comparison with phosphorylase b as substrate.
There was no difference in the activation or inhibition observed
between the two substrates, using either phosphorylase kinase
holoenzyme or the gzd complex, with regard to any of the three
antibodies examined.
DISCUSSION
The purpose of this study was to characterize monospecific
antibodies raised against peptides spanning the regulatory
domain of the g-subunit of phosphorylase kinase to determine
whether any of these antibodies might have an effect on the
biochemical properties of the enzyme. Antipeptide antibodies
have previously been used to identify important functional
domains in other protein kinases by characterizing the effects
of antibody binding on enzyme activation and inhibition (12–
17). Antibodies capable of activating or inhibiting phosphoryl-
ase kinase have also been raised using native phosphorylase
kinase holoenzyme and denatured subunits of phosphorylase
kinase as antigens (26–28). However, most of the epitopes of
these antiphosphorylase kinase antibodies have not been pre-
cisely localized, so that it is difficult to interpret the effects of
these antibodies in terms of their binding to specific structural
elements within the holoenzyme. In the present study, the
effects of each antibody on enzymatic activity can be inter-
preted in terms of that antibody’s binding to a specific region on
the regulatory domain of the g-subunit, since the antibody’s
epitope is defined by the peptide antigen used in raising it.
Because of the complex subunit structure and enzymology of
phosphorylase kinase, the effects of each regulatory domain
antibody were determined using two different catalytic forms of
the enzyme, the holoenzyme and the gzd complex. The former
catalytic form contains a full complement of subunits, whereas
the latter catalytic form lacks the regulatory a- and b-subunits.
All of the g-subunit regulatory domain antipeptide antibodies
were found to have some sort of effect on the enzymatic activity
of phosphorylase kinase, with the C-terminal regulatory do-
main antibodies (anti-PhK1 and anti-PhK5) stimulating activ-
ity and the antibodies raised against the N-terminal region of
the regulatory domain (anti-PhK9 and anti-PhK13) being
inhibitory.
The activating effects of the two antibodies specific for the C
terminus of the regulatory domain of the g-subunit, anti-PhK1
and anti-PhK5, were qualitatively the same in nearly every
respect. Both were able to stimulate the activity of holoenzyme
and gzd complex in the presence and absence of Ca21 (Figs. 2
and 3), with anti-PhK1 consistently having the greater effect.
Calcium ion was required for maximal antibody activation with
both antibodies, regardless of which enzymatic form of phos-
phorylase kinase was used. In the absence of Ca21, both anti-
bodies were able to stimulate enzymatic activity to levels com-
parable with that seen with Ca21 in the absence of antibody.
These data suggest that anti-PhK1 and anti-PhK5 affect the
activity of phosphorylase kinase through a similar mechanism
that involves a conformational change within the regulatory
domain of the g-subunit. Since the region corresponding to
PhK5 is thought to serve as a calmodulin-binding subdomain
(9) and as a pseudosubstrate/autoinhibitory subdomain (6, 10),
FIG. 8. Kinetic scheme and equation for partial noncompeti-
tive inhibition of phosphorylase kinase holoenzyme activity by
anti-PhK13 antibody. [S] is the concentration of phosphorylase b; Ks
is the Michaelis constant for phosphorylase b; v/Vmax is the fractional
activity; [I] is the concentration of anti-PhK13 antibody; Ki is the
inhibition constant (in mg/ml); and a is the partial inhibition coefficient.
For the sake of simplicity and because anti-PhK13 had no effect on the
Km for ATP, the kinetic scheme and equation do not include the sub-
strate, ATP. The values for a and Ki were determined by nonlinear
curve fitting of the data in Fig. 7 using MacCurveFit (version 1.03).
FIG. 9. Antibody activation and inhibition of phosphorylase
kinase holoenzyme and gzd complex with phosphorylase b or
synthetic peptide substrate. Phosphorylase kinase (A) or the gzd
complex (B) was assayed at pH 8.2 following incubation with anti-
PhK1, anti-PhK5, or anti-PhK13 antibody and using either phospho-
rylase b (filled bars) or peptide substrate (open bars) in the presence or
absence of Ca21 as indicated. Conditions of the assay are described
under “Experimental Procedures.” Error bars represent the standard
error of the mean of three independent assays (each performed in
duplicate).
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it seems likely that antibody-induced structural changes that
overcome the inhibitory capacity of the PhK5 region are re-
sponsible for activating phosphorylase kinase. Interestingly,
the region corresponding to PhK1 appears to have no measur-
able calmodulin-binding activity or pseudosubstrate-like activ-
ity (9, 10). However, it is not difficult to imagine that anti-PhK1
binding to the g-subunit might be capable of inducing struc-
tural changes in the proximal PhK5 region (cf. Fig. 1). The
greater effects of anti-PhK1 compared with anti-PhK5 are dif-
ficult to explain except that perhaps anti-PhK1 binding induces
larger structural changes in the regulatory domain than the
binding of anti-PhK5. The effects of anti-PhK1 and anti-PhK5
on catalytic activity were predominantly or entirely through an
effect on Vmax, although some rate-enhancing effects on the Km
for phosphorylase b were also seen with anti-PhK1, particu-
larly with the gzd complex (Table I). These results are consist-
ent with the data of Newsholme and Walsh (29), which showed
that activation of phosphorylase kinase at pH 6.8 by Ca21 and
by phosphorylation of the a- and b-subunits was predominantly
due to changes in Vmax. It is interesting to note that Jennissen
et al. (28) also observed activation of the holoenzyme through a
Vmax mechanism with antibodies raised against purified g- and
b-subunits of phosphorylase kinase. The epitopes of these poly-
clonal antibodies were not determined.
The degree to which the C-terminal region of the g-subunit
regulatory domain (g342–386) interacts with the a- and b-sub-
units can be inferred from differences in activation seen be-
tween the holoenzyme and the gzd complex and the effects of a-
and b-subunit phosphorylation on antibody-induced activation.
The most obvious difference between antibody-induced activa-
tion of holoenzyme versus gzd complex is that the magnitude of
activation observed with holoenzyme is generally severalfold
greater than that seen with the gzd complex (Table I). One
possibility for this difference is that in the nonactivated holoen-
zyme, the a- and b-subunits are acting to suppress activity and
that anti-PhK1 and anti-PhK5 relieve this supression. Indeed,
it is generally thought that the a- and b-subunits are inhibi-
tory, since their dissociation, phosphorylation, or proteolysis
results in enzyme activation (reviewed in Ref. 1). Phosphoryl-
ation of the a- and b-subunits by incubation with cAMP-de-
pendent protein kinase and MgATP effectively blocked anti-
body-induced activation (Fig. 6), providing additional evidence
that the regions corresponding to PhK1 and PhK5 are involved
in a- and/or b-subunit regulation of holoenzyme activity. The
mechanism by which phosphorylation inhibits antibody-in-
duced activation is presently unknown, but there are two likely
possibilities. The first is that phosphorylation prevents the
antibodies from binding to the g-subunit regulatory domain.
The second is that prior phosphorylation of the a- and/or b-sub-
unit locks the g-subunit regulatory domain into a conformation
that cannot be altered by antibody binding. Studies are pres-
ently underway to distinguish these two possibilities, but re-
gardless of the mechanism involved, these data suggest a tight
coupling of structural changes in the a- and/or b-subunits to
structural changes in the C-terminal 45 residues of the
g-subunit.
The activation of phosphorylase kinase by anti-PhK1 ap-
pears to require antibody with intact Fc domains based on
studies using Fab fragments of this antibody (Fig. 4). Neither
the holoenzyme nor the gzd complex were activated by anti-
PhK1 Fab fragments, even though the Fab fragments were able
to bind both phosphorylase kinase and the gzd complex as
shown by a sandwich ELISA (Fig. 5). These data suggest that
binding of the second arm of an antibody molecule to an adja-
cent g-subunit regulatory domain is required for activation.
Thus, antibody-induced activation may be a consequence of
both arms of an intact antibody molecule simultaneously bind-
ing to the enzyme, which then imparts a leveraging action to
the g-subunit regulatory domain. It is interesting to consider
whether some sort of mechanical activation such as this might
be an important but heretofore unrecognized mechanism for
activating muscle phosphorylase kinase in response to con-
tractile activity. Based on the effects of anti-PhK1 and anti-
PhK5 reported here, mechanical activation could be superim-
posed on Ca21-induced activation, would be relatively
independent of cellular pH, and would be blocked by phospho-
rylation of the enzyme. We are currently designing experi-
ments to test whether mechanical activation might represent
an important physiological means of regulating phosphorylase
kinase activity in muscle. It is not clear why intact antibody
should also be required for activation of the gzd complex (Fig. 4),
since this complex is thought to exist as a simple heterodimer
(30). One possibility is that antibody binding might facilitate
the formation of a (gzd)2 or (gzd)4 complex that is then activated
by antibody as in the holoenzyme complex.
In contrast to the activating effects of anti-PhK1 and anti-
PhK5, the antibodies raised against the N terminus of the
g-subunit regulatory domain exhibited inhibitory effects on
phosphorylase kinase activity. The effects of anti-PhK9 were
very weak with regard to inhibition of the holoenzyme and the
gzd complex (Figs. 2 and 3), although overnight incubation of
anti-PhK9 with the gzd complex elicited essentially complete
inhibition (data not shown). The antibody to PhK13 could only
partially inhibit the activity of the holoenzyme (Figs. 1, 3, and
5) but was able to completely inhibit the activity of the gzd
complex (Figs. 2 and 5). The differences in inhibition with
respect to phosphorylase kinase holoenzyme and the gzd com-
plex are most likely due to the presence of the a- and b-sub-
units in the holoenzyme, which may interfere with the ability of
these antibodies to elicit complete inhibition.
There are at least two mechanisms by which anti-PhK9 and
anti-PhK13 might inhibit the activity of phosphorylase kinase.
The first possibility is that these antibodies might trap the
regulatory domain in a conformational state that prevents ac-
tivation. This seems a likely possibility, since PhK13 is thought
to function as both a calmodulin-binding subdomain (9) and as
an autoinhibitory/pseudosubstrate subdomain (10). Moreover,
this mechanism of antibody-induced inhibition has previously
been shown to operate in the case of tryptophan synthase,
where an antibody to the b2-subunit prevented or restricted
molecular movements associated with substrate binding dur-
ing the catalytic cycle (31). An alternative explanation for in-
hibition by anti-PhK9 and anti-PhK13 is that antibody binding
to the N-terminal region of the regulatory domain causes steric
hindrance of the catalytic site. Kinetic analysis of anti-PhK13
inhibition should make it possible to distinguish between these
two alternative mechanisms. Steric hindrance would be ex-
pected to result in a change in Km for phosphorylase b, whereas
a mechanism involving restriction of conformational changes
would be predicted to cause a reduction in Vmax. The kinetic
data obtained for anti-PhK13 (Table I) are consistent with this
antibody acting through a mechanism that restricts conforma-
tional changes in the regulatory domain, since anti-PhK13
acted as a noncompetitive inhibitor of phosphorylase kinase
activity. If the mechanism of inhibition by anti-PhK13 were to
involve steric hindrance of the protein substrate, then the use
of a smaller phosphate-acceptor substrate might at least par-
tially alleviate the inhibitory effects of the antibody. However,
the use of a tetradecapeptide phosphate-acceptor substrate
instead of phosphorylase b had no effect on the efficacy of
anti-PhK13 with regard to either holoenzyme or gzd inhibition
(Fig. 6). This adds further support to the idea that anti-PhK13
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acts by preventing conformational changes in the g-subunit
regulatory domain important for full catalytic efficiency. It is
worth noting that a g-subunit monoclonal antibody whose
epitope has been identified as being just N-terminal to PhK13
(residues 277–290) activates the holoenzyme approximately
2-fold at pH 6.8 (32).2 This region of the g-subunit is thought to
be a linker region between the catalytic and regulatory do-
mains. The kinetic mechanism of the activation by this anti-
body is not yet known, but it is interesting that it binds closely
to where anti-PhK13 binds but elicits an opposite effect on
activity.
Experiments comparing the effect of incubation time on an-
tibody-induced activation and inhibition (data not shown) sug-
gest that certain conformational states in phosphorylase ki-
nase are relatively slow to form. In the case of anti-PhK5,
significantly greater activation of the holoenzyme was observed
after 24 h of incubation with the antibody than after a 1-h
incubation. This effect appeared to be dependent upon the
presence of the a- and/or b-subunits, since no such time-de-
pendent effect was observed for anti-PhK5 with the gzd com-
plex. Proteolysis of the a- and/or b-subunits is known to result
in activation of the holoenzyme (reviewed in Ref. 1), but this is
unlikely to be the mechanism for slow activation with anti-
PhK5, since no significant time-dependent activation was seen
with the control incubation or with the other antibodies. More-
over, inhibition of holoenzyme by anti-PhK13 was also mark-
edly time-dependent, as was inhibition of the gzd complex by
anti-PhK9. The slow rates of activation and inhibition noted
above are unlikely to be due to diffusional effects, since an
equilibrium between bound and free antibody should be
reached in well under an hour with the concentrations of anti-
body and enzyme used in the incubations. The fact that differ-
ent time-dependent effects were observed with different forms
of phosphorylase kinase also argues against slow diffusional
effects being the reason for slow activation or inhibition. One
possible mechanism to explain the delayed effects of antibody
on catalytic activity is that the enzyme may need to undergo a
slow conformational change before antibody can bind. Another
possibility is that the enzyme undergoes a slow conformational
change after antibody is bound. A third possibility is that slow-
acting antibodies are only able to bind to a very infrequent or
low probability conformational state in a highly mobile region
of the enzyme. At present, we are unable to distinguish among
these several mechanisms. However, because gradual changes
in phosphorylase kinase catalytic activity could have important
physiological consequences, it will be important to characterize
the underlying mechanisms in future studies and to determine
whether they are operative in situ.
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Note Added in Proof—It has come to our attention that the idea for
the possibility of the mechanical activation of phosphorylase kinase
linked to muscle contraction has been independently proposed by Dr.
Gerald M. Carlson and co-workers of the University of Tennessee,
Memphis based on structural studies that localized a region of the
enzyme’s inhibitory b-subunits to near the contact points between
dimers in the tetrahedral dimer of dimers, which describes the holoen-
zyme. It was hypothesized that slight mechanical rotation of the lobes
could activate the enzyme by mimicking the structural changes that
typically occur when tetrahedral dimers of dimers undergo T to R
transitions in response to ligands.
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